Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Foundation launches Harvard research hub

The foundation and the Broad Institute have joined up to launch the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative...

Novalis Biotech closes biotech fund at €25m

According to the Belgium-headquartered venture capital specialist, the  investor base includes institutional investors, such as Participatie...

€26m financing for ISA Pharmaceuticals

New investors of the company, including Invest-NL, joined existing investors, among them Regeneron. ISA, which is located in Leiden Bio Science Park,...

EuropaBio lobbies for better Orphan Drug rules

The Orphan Drug Regulation adopted in 2000 should be improved to incentivise even ultra-rare conditions with high unmet medical need, according to...

Coriolis Pharma expands its ATMP development facilities

The cell and gene therapy formulation R&D specialist will add a BSL2 facility, totaling Coriolis Pharma’s floor space to 7,800 m2. The new...

AXA IM Alts raises €1.9bn European Life Sciences Fund

The capital was raised over the last seven months, with commitments to a significantly oversubscribed fund raise from a range of clients from North...

Novo Nordisk invests in amyloidosis pipeline

Novo Nordisk is known as a major player in diabetes treatment, but now the Danish pharma company seems eager to add to this indication. It announced...